• Journal of Chest Surgery
• /
• v.35 no.5
• /
• pp.381-386
• /
• 2002

Background: Bronchial carcinoids account for approximately 2% of all pulmonary tumor and consist of typical carcinoids and atypical carcinoids. An atypical carcinoids is considered to be an intermediate form of tumor between a low-grade malignant typical carcinoid and a high-grade malignant small cell lung carcinoma. There is still controversy with regard to the extent of resection and the value of systemic adjuvant therapy in atypical carcinoids. We performed a retrospective review of our experiences at Severance Hospital. Material and Method: Between 1990 and 2000, 15 patients with bronchial carcioids were operated, and 5 of these had atypical carcinoids. Histologic diagnosis was established un the criteria of WHO/IASLC(1999). Result: There were 3 pneumonectomies, 11 lobectomies, and 1 segmentectomy. In typical carcinoids, one patient had regional lymph node metastasis, and 3 patients in atypical carcinoids had mediastinal lymph node metastases. Distant metastases developed in one patient of typical carcinoid, but developed in 4 patients of atypical carcinoids(p=0.0017). The 5-year survival rate in patients with atypical carcinoids was 20%, versus the 100% 5-year survival rate observed in patients with topical carcinoids(p=0.0039). Conclusion: In atypical carcincids, because of many lymph node metastases on diagnosis and a low long-term survival rate, lobectomy constitutes a mininal procedure. Adjuvant systemic therapy is recommended fur patients with lymph node and distant metastasis.

• Journal of Chest Surgery
• /
• v.25 no.11
• /
• pp.1236-1239
• /
• 1992

Carcinoid tumors arising in the thymus are rare. Since Rosai and Higa in 1972 distinguished these neoplasms from thymomas, fewer than 100 cases have been reported in the world literature. The pathologic diagnosis of thymic carcinoids is been on findings from light microscopy, histochemical studies, and electron microscopy. About 50% of thymic carcinoids are seen with endocrinopathies. Recurrence and extrathoracic metastasis are characteristic of thymic carcinoids. Surgical extirpation of the tumor initially and of the subseguent recurrences in the most effective treatment today The role of adjuvant radiotherapy and chemotherapy is still uncertain. Herein we report a case of thymic carcinoid tumor in a 36-year old male with brief review of literatures.

• Journal of Chest Surgery
• /
• v.35 no.4
• /
• pp.325-328
• /
• 2002

The neuroendocrine tumor is a rare thymic neoplasm, which has been regarded as a distinct tumor from thymoma and originates from Kultschizky cell. The pathologic diagnosis of thymic neuroendocrine tumor has been on findings from light microscopy, immunohistochemical studies, and electron microscopy. About 50% of thymic carcinoids are seen with endocrinopathies. Recurrence and extrathoracic metastasis are characteristics of thymic carcinoids. Surgical removal of the initial and recurred tumor is considered to be the most effective treatment. The role of the adjuvant chemotherapy and radiotherapy is still uncertain. Herein we report a case of thymic neuroendocrine tumor, which was resected surgically.

• Journal of Chest Surgery
• /
• v.31 no.3
• /
• pp.319-323
• /
• 1998

Thymic carcinoid tumor is a rare mediastinal tumor, which was firstly described by Rosai and Higa in 1972. A carcinoid tumor of the thymus has recently been regarded as a distinct tumor from thymoma, and is probably Kultschizky cell origin. The pathologic diagnosis of thymic carcinoid is made from findings from light microscopy, immunohistochemical studies and electron microscopy. About 50% of thymic carcinoids were seen with endocrinopathies. Recurrences and extrathoracic metastasis are characteristics of thymic carcinoids. Surgical removal of the intial and tumor recurred are considered to be the most effective treatment today. However, the role of the adjuvant radiotherapy and the chemotherapy is still uncertain. Herein we report a case of thymic carcinoid tumor, which was confirmed by operation and pathologic study.

• Tuberculosis and Respiratory Diseases
• /
• v.43 no.3
• /
• pp.440-448
• /
• 1996

Bronchial carcinoid tumors are uncommon, constituting approximately 3-5% of all primary lung cancers. Classification of these tumors has evolved substantially as our understanding of the cellular, biologic, and clinical aspects of these neoplasms has improved. Initially, bronchial carcinoids were thought to be benign and therefore were classified as bronchial adenomas. Currently, however, they are well recognized as having the potential for both local invasion and distant metastatic involvement. Consequently, carcinoid tumors are frankly malignant. Thus bronchial adenoma is a misnomer that should no longer be used for bronchial carcinoids. Most investigators currently favor classifying carcinoid tumors as a type of neuroendocrine neoplasm because of their potential to secrete a variety of chemical substances found in both the central nervous system and the epithelial cells of numerous organs. Bronchial carcinoids are usually characterized by a slow growth pattern and a low incidence of metastasis, and histologically conformed by the azurophil staining and the presence of the characteristic neurosecretary granule on electron microscopy. Atypical carcinoid tumor was first defined by Arrigoni et al, who proposed the following criteria for separation of atypical carcinoid from typical carcinoid tumor : 1) increased mitotic activity with 1 mitotic figure per 1-2 high power fields(or 5-10 mitoses /10 HPF), 2) nuclear pleomorphism, hyperchromatism, and an abnormal nuclear-cytoplasmic ratio, 3) areas of increased cellularity with disorganization of the architecture, and 4) tumor necrosis. In contrast, typical carcinoid tumor may have focal cytologic pleomorphism, but necrosis is absent and mitotic figures are rare. Recently we experienced a case of atypical bronchial carcinoid with multiple distant metastasis, so we report this case with a review of the literature.

• Journal of Chest Surgery
• /
• v.34 no.11
• /
• pp.887-890
• /
• 2001

Neuroendocrine tumor in thymus is rare and has poor prognosis due to frequent recurrence and distant metastasis. Approximately half of thymic carcinoids are hormonally active and Cushing\`s syndrome is seen in 33% of affected patients. Treatment of choice is surgical excision of tumor and role of chemotherapy and radiotherapy is controversal. We report 2 cases of thymic neuroendocrine carcinoma associated with Cushing\`s syndrome.

• Tuberculosis and Respiratory Diseases
• /
• v.40 no.1
• /
• pp.67-71
• /
• 1993

Bronchial carcinoids were classified as one of the bronchial adenoma group and constituted about 90% of bronchial adenoma. Typical carcinoids are common benign neoplasms of the airway because of their uniform histologic feature, predictable clinical course and good survival after surgical resection. And atypical carcinoid is regarded as a malignant tumor because of its pleomorphic, hyperchromatic nucleus, frequent mitosis and distant metastasis (about 70%). However, typical carcinoids rarely metastasize to regional lymph nodes and such cases would be regarded as a low grade malignancy because their clinical prognosis could be bad. We present a case of typical bronchial carcinoid which metastasize to hilar lymph node who has been followed up 10 months after resection.

• Journal of Chest Surgery
• /
• v.36 no.1
• /
• pp.47-50
• /
• 2003

Pulmonary carcinoid tumors are thought to Originate from neuroendocrine Kulchitsky's cells in the bronchial epithelium. The majority of typical carcinoid tumors arc located centrally. However, atypical carcinoids are frequently situated peripherally and display malignant histologic features with aggressive behavior. Few reports arc discribing carcinoid tumors originating from the pleura. We report a typical carcinoid tumor located mainly in the parietal pleura invading the chest wall wilhout evidence of pulmonary parenchymal invasion.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• v.10 no.1
• /
• pp.86-90
• /
• 2007

Carcinoid tumors are derived from the enterochromaffin cells of neural crest origin. Most are commonly found in the gastrointestinal (GI) tract. The rectum is the third most common site for GI carcinoids. Rectal carcinoid tumors make up 13.7% of all carcinoid tumors and the vast majority occurs in the sixth decade of life. Approximately 80% of rectal carcinoid tumors are less than 1 cm in size, limited to the submucosa without metastasis and can be safely treated by local excision. We report a case of rectal carcinoid tumor in a 13 year-old child that was successfully treated by endoscopic polypectomy.

• Journal of Digestive Cancer Research
• /
• v.3 no.1
• /
• pp.21-25
• /
• 2015

Gastric neuroendocrine tumors (GNETs, also known as gastric carcinoids) are rare form of hormone-secreting neoplasms that present with varied clinical syndromes. There are four types of GNETs based on size, proliferation, localization, differentiation, and hormone production. Type I GNET is related to autoimmune atrophic gastritis and hypergastrinemia. Type II GNETs are related to multiple endocrine neoplasia (MEN)-1, Zollinger-Ellison syndrome and hypergastrinemia. Type 3 GNETs are not associated with any background pathology, and type 4 GNETs are poorly differentiated tumors. The most useful diagnostic and prognostic marker for gastrointestinal NETs is plasma chromogranin A (CgA) levels. Endoscopic ultrasound is the method of choice to determine tumor size and depth of infiltration. For optimal management, the type, biology, and stage of the tumor must be considered. Here, we provide a comprehensive and up-to-date review of GNETs.